Contineum Therapeutics, Inc.’s (NASDAQ:CTNM) Quiet Period Will Expire on May 15th

Contineum Therapeutics’ (NASDAQ:CTNM) quiet period is set to expire on Wednesday, May 15th. Contineum Therapeutics had issued 6,875,000 shares in its public offering on April 5th. The total size of the offering was $110,000,000 based on an initial share price of $16.00. During the company’s quiet period, insiders and any underwriters that worked on the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analysts Set New Price Targets

CTNM has been the topic of a number of research reports. Morgan Stanley started coverage on shares of Contineum Therapeutics in a report on Tuesday, April 30th. They issued an “overweight” rating and a $25.00 price objective on the stock. Stifel Nicolaus began coverage on shares of Contineum Therapeutics in a research note on Tuesday, April 30th. They set a “buy” rating and a $29.00 price target on the stock. Finally, Royal Bank of Canada started coverage on shares of Contineum Therapeutics in a research report on Tuesday, April 30th. They set an “outperform” rating and a $30.00 price objective for the company.

Contineum Therapeutics Stock Down 0.1 %

CTNM stock opened at $14.81 on Wednesday. Contineum Therapeutics has a twelve month low of $13.27 and a twelve month high of $16.06.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).